HanchorBio and Henlius Forge Global Alliance to Advance Immuno-Oncology Through HCB101 Licensing Deal
FOR IMMEDIATE RELEASE
[CITY, STATE] – July 1, 2025 – HanchorBio, a pioneering biopharmaceutical company at the forefront of immuno-oncology innovation, and Henlius, a leading global biopharmaceutical company dedicated to the development and commercialization of high-quality biopharmaceuticals, today announced a significant milestone with the signing of a major licensing agreement for HanchorBio’s promising investigational drug candidate, HCB101. This strategic partnership is poised to expand the global reach of this innovative therapy, offering new hope to patients battling various forms of cancer.
HCB101 represents a novel approach to harnessing the body’s immune system to fight cancer. While specific details regarding the exact mechanism of action and target indications for HCB101 were not fully disclosed in the initial announcement, its positioning within the immuno-oncology landscape signifies its potential to address unmet medical needs in a rapidly evolving field. The agreement grants Henlius rights to develop, manufacture, and commercialize HCB101 in designated territories, underscoring the shared commitment of both companies to accelerating access to life-changing treatments.
This collaboration leverages HanchorBio’s expertise in groundbreaking immuno-oncology research and development with Henlius’s established global presence, robust manufacturing capabilities, and extensive commercialization infrastructure. By joining forces, the companies aim to expedite the clinical development, regulatory approval, and subsequent market access of HCB101, ultimately benefiting patients worldwide.
“We are delighted to partner with Henlius, a company that shares our vision for transforming cancer treatment through innovative immuno-oncology therapies,” said [Name and Title of HanchorBio Representative, if available, otherwise use “a spokesperson for HanchorBio”]. “This licensing agreement represents a critical step forward in our mission to bring HCB101 to patients who need it most. Henlius’s proven track record and global footprint make them an ideal partner to maximize the therapeutic potential of HCB101 and deliver it to a broad patient population.”
The agreement is expected to provide HanchorBio with significant upfront payments and milestone-based payments, as well as royalties on future sales of HCB101. This financial backing will further enable HanchorBio to continue its ongoing research and development efforts, including the advancement of its pipeline of next-generation immuno-oncology assets.
[Name and Title of Henlius Representative, if available, otherwise use “a spokesperson for Henlius”] commented, “This collaboration with HanchorBio marks an exciting expansion of our immuno-oncology portfolio and reinforces our commitment to providing innovative and accessible therapies to patients globally. HCB101 has demonstrated significant promise, and we are confident that our expertise in clinical development and commercialization will enable us to successfully bring this therapy to patients in need.”
The immuno-oncology sector continues to be a dynamic and rapidly advancing area in oncology, with treatments aimed at stimulating the patient’s own immune system to recognize and attack cancer cells. This licensing deal between HanchorBio and Henlius signifies a shared belief in the transformative power of this therapeutic modality and a dedication to making these cutting-edge treatments a reality for patients facing challenging diagnoses.
Further details regarding the specific terms of the licensing agreement and the planned development and commercialization strategy for HCB101 are anticipated to be released in due course. Both companies are committed to transparency and to keeping stakeholders informed as this important collaboration progresses.
About HanchorBio: HanchorBio is a clinical-stage biopharmaceutical company focused on discovering and developing novel immuno-oncology therapies to address significant unmet medical needs in cancer. With a strong emphasis on cutting-edge science and a commitment to patient well-being, HanchorBio is dedicated to bringing innovative solutions to the oncology landscape.
About Henlius: Henlius is a global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative and high-quality biopharmaceuticals. With a focus on oncology, autoimmune diseases, and other major diseases, Henlius aims to provide accessible and affordable treatments to patients worldwide.
Contact:
For HanchorBio: [HanchorBio Media Contact Name] [HanchorBio Media Contact Title] [HanchorBio Media Contact Email] [HanchorBio Media Contact Phone Number]
For Henlius: [Henlius Media Contact Name] [Henlius Media Contact Title] [Henlius Media Contact Email] [Henlius Media Contact Phone Number]
###
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach’ at 2025-07-01 05:40. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.